Insider Transactions in Q4 2023 at Becton Dickinson & CO (BDX)
Insider Transaction List (Q4 2023)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 11
2023
|
Michael David Garrison EVP & President, Medical |
SELL
Open market or private sale
|
Direct |
1,239
-14.55%
|
$287,448
$232.46 P/Share
|
Nov 28
2023
|
Richard Byrd EVP & President Interventional |
SELL
Open market or private sale
|
Direct |
2,156
-34.35%
|
$513,128
$238.47 P/Share
|
Nov 26
2023
|
David Hickey EVP & President, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
1,663
+22.1%
|
-
|
Nov 26
2023
|
Thomas J Spoerel SVPController & Chief Acct Off |
SELL
Payment of exercise price or tax liability
|
Direct |
365
-12.34%
|
-
|
Nov 26
2023
|
Thomas J Spoerel SVPController & Chief Acct Off |
BUY
Grant, award, or other acquisition
|
Direct |
1,132
+17.46%
|
-
|
Nov 26
2023
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
258
-1.39%
|
-
|
Nov 26
2023
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,659
+8.2%
|
-
|
Nov 26
2023
|
Pavan Kumar Mocherla EVP & President Greater Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-3.4%
|
-
|
Nov 26
2023
|
Pavan Kumar Mocherla EVP & President Greater Asia |
BUY
Grant, award, or other acquisition
|
Direct |
751
+17.63%
|
-
|
Nov 26
2023
|
Michael David Garrison EVP & President, Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
1,646
-16.2%
|
-
|
Nov 26
2023
|
Michael David Garrison EVP & President, Medical |
BUY
Grant, award, or other acquisition
|
Direct |
5,002
+22.29%
|
-
|
Nov 26
2023
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
812
-5.67%
|
-
|
Nov 26
2023
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,325
+18.84%
|
-
|
Nov 26
2023
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
1,509
-19.38%
|
-
|
Nov 26
2023
|
Richard Byrd EVP & President Interventional |
BUY
Grant, award, or other acquisition
|
Direct |
4,341
+24.97%
|
-
|
Nov 26
2023
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
149
-2.53%
|
-
|
Nov 26
2023
|
David Shan EVP and Chief ISC Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,408
+18.65%
|
-
|
Nov 26
2023
|
Michelle Quinn EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
440
-8.16%
|
-
|
Nov 26
2023
|
Michelle Quinn EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,115
+17.8%
|
-
|
Nov 26
2023
|
Roland Goette EVP and President, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
213
-1.15%
|
-
|
Nov 26
2023
|
Roland Goette EVP and President, EMEA |
BUY
Grant, award, or other acquisition
|
Direct |
3,190
+7.9%
|
-
|
Nov 26
2023
|
Antoine C Ezell EVP, President Americas & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,654
-14.69%
|
-
|
Nov 26
2023
|
Antoine C Ezell EVP, President Americas & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
4,069
+16.09%
|
-
|
Nov 16
2023
|
Roland Goette EVP and President, EMEA |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,751
-10.2%
|
$411,485
$235.07 P/Share
|
Nov 16
2023
|
Roland Goette EVP and President, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
3,544
+17.11%
|
$379,208
$107.12 P/Share
|